Ranolazine extended release - Gilead Sciences
Alternative Names: CORZYNA; CVT 303; CVT 3041; KEG 1295; RAN D; Ran4; Ranexa; Ranolazine hydrochloride; RS 43285; RS 43285-003; RS 43285-193; ™CORZYNA™Latest Information Update: 07 May 2021
At a glance
- Originator Syntex Pharmaceuticals International
- Developer CV Therapeutics; Gilead Sciences; Kissei Pharmaceutical; KYE Pharmaceuticals; Menarini; North Shore-Long Island Jewish Health System; Ohio State University; University of Rochester
- Class Acetanilides; Anti-ischaemics; Antiarrhythmics; Antihyperglycaemics; Ischaemic heart disorder therapies; Piperazines; Small molecules; Vasodilators
- Mechanism of Action Partial fatty acid oxidation inhibitors; Pyruvate dehydrogenase stimulants; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Angina pectoris
- Phase III Acute coronary syndromes; Atrial fibrillation; Type 2 diabetes mellitus
- Phase II Aortic valve stenosis; Diastolic heart failure; Left ventricular hypertrophy; Long QT syndrome; Myocardial ischaemia; Myotonic dystrophy
- Discontinued Intermittent claudication; Ventricular arrhythmias
Most Recent Events
- 04 May 2021 Launched for Angina pectoris (Adjunctive treatment) in Canada (PO)
- 28 Jan 2021 A.Menarini Asia-Pacific Holdings completes a phase I trial in healthy volunteers in South Korea (NCT02817932)
- 31 Dec 2020 Gilead Sciences has patent protection for ranolazine extended release the European Union